Darunavir/cobicistat, sold under the brand names Prezcobix (US) and Rezolsta (EU), is an antiretroviral medication used to treat and prevent HIV/AIDS. It is a fixed dose combination drug containing 800 mg of darunavir and 150 mg of cobicistat. Darunavir is an HIV protease inhibitor and cobicistat increases the effectiveness of darunavir by blocking its metabolism by the enzyme CYP3A.

Darunavir/cobicistat was approved for use in the European Union in November 2014, and for use in the United States in January 2015.

Rujukan

Pranala jaba
 
 
 

Antiretroviral drugs
Fixed dose combination (antiretroviral)